[110:40] Andrew Huberman I sent out a little informal poll to the
Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
If those instructions are unclear, call and ask specifically about temperature requirements and room temperature tolerance
Study Design Type: Phase 2, double-blind, randomized, placebo-controlled study Participants: 338 adults (BMI 30 or BMI 27 with a coexisting condition) Groups: Retatrutide 1 mg, 4 mg, 8 mg, 12 mg (different initial doses 2 or 4 mg) and placebo Duration: 48 weeks (plus 4 weeks follow-up) Administration: subcutaneous, 1x weekly Primary endpoint: percentage change in body weight at week 24 Secondary endpoints: change in weight at week 48, 5%, 10%, 15% weight reduction
Keep product in the original carton to protect from light until the time of use
3 Mechanistic reviews discuss BPC-157s bidirectional effects on angiogenesis/NOmitigating damaging cascades while supporting protective vascular functions (preclinical context)